The Filing Desk

Caris Life Sciences vs Pennant Group

Caris Life Sciences CAI · Pennant Group PNTG · Health Care Services

Pennant Group reported revenue of $948 million in fiscal 2025, 1.2 times Caris Life Sciences' $812 million in fiscal 2025. Caris Life Sciences' revenue grew 97.0% in its latest year, and Pennant Group's grew 36.3%. Caris Life Sciences had an operating margin of 5.6%, against 5.5% at Pennant Group. Free cash flow was $67 million at Caris Life Sciences and $36 million at Pennant Group.

Side by side

Caris Life SciencesPennant Group
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$812M$948M
Revenue growth97.0%36.3%
Revenue growth a year, last 5 years—19.4%
Gross margin——
Operating margin5.6%5.5%
Net margin−8.4%3.1%
Free cash flow$67M$36M
Free cash flow margin8.2%3.8%
Return on capital—9.3%
Net debt to EBITDA−6.2x2.6x
Dividends and buybacks$0M$0M
Change in diluted share count371.0%10.4%
Last close$18.54$34.09
P/E at the last close—34.1×
Insider trades, last 12 monthsbought $1.5 million, sold $28.9 millionsold $698,185
Piotroski F-score—5 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Caris Life SciencesPennant Group
Operating margin
Percent of revenue
Caris Life SciencesPennant Group
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Caris Life SciencesPennant Group

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Caris Life Sciences and Pennant Group pages.